The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Baxter International's revenues will expand 3.7% and EPS will grow 0.9%.
The average estimate for revenue is $3.70 billion. On the bottom line, the average EPS estimate is $1.13.
Last quarter, Baxter International tallied revenue of $3.45 billion. GAAP reported sales were 1.8% higher than the prior-year quarter's $3.39 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $1.05. GAAP EPS of $1.00 for Q1 were 3.8% lower than the prior-year quarter's $1.04 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 50.9%, 30 basis points better than the prior-year quarter. Operating margin was 21.2%, 70 basis points better than the prior-year quarter. Net margin was 16.0%, 140 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $15.48 billion. The average EPS estimate is $4.66.
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 642 members out of 673 rating the stock outperform, and 31 members rating it underperform. Among 220 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 215 give Baxter International a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Baxter International is outperform, with an average price target of $72.19.
Is Baxter International the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Baxter International to My Watchlist.